UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2018 » Volume 26, issue 2 (95) » Place of olatropil in treatment of cognitive disorders in patients with multiple sclerosis

Place of olatropil in treatment of cognitive disorders in patients with multiple sclerosis

Authors

Type of Article

  • Scientific Article

In the Section

  • MECHANISMS OF FORMATION AND MODERN PRINCIPLES OF TREATMENT OF NEUROLOGICAL DISORDERS

Key words

Index UDK:
  • 616.832-004.2-06:616.8:615.21

Abstract

The article deals with the treatment of cognitive disorders in patients with multiple sclerosis. For the purpose of studying the effi cacy of olatropil, 60 patients with cognitive dysfunction were examined. The obtained data showed the presence of mild to moderate dementia in all patients. The use of olatropil in combination therapy contributes to improving the eff ectiveness of therapy by reducing anxiety, improving cognitive performance, especially after receiving a complete course of therapy

Pages

  • 22-25

Year / Issue

Download PDF

References

  1. Multiple sclerosis in Ukraine: prevalence, course, prognosis, treatment, pharmacoeconomics / Voloshin P. V., Voloshyna N. P., Taytslin V. Y. [et al.] // Ukrainian Journal of Psychoneurology. 2007. Vol. 15, issue 1 (50). Pp. 6–21.
  2. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis / Marrie R. A., Rudick R., Horwitz R. [et al.] // Neurology. 2010. № 74. Р. 1042—1047.
  3. Impact of electroacupuncture on quality of life for patients with relapsing-remitting multiple sclerosis under treatment with immunomodulators: a randomized study / Quispe-Cabanillas J. G., Damasceno , von Glehn F. [et  al.]  // BMC Complementary and Alternative Medicine. 2012, 12: 209. Р. 1—7.
  4. Malik O., Donnelly A., Barnett M. Fast Facts: Multiple sclerosis. Oxford : Health Press limited, 2014. 136 p.
  5. Multiple sclerosis: Unified clinical protocol for primary, secondary (specialized), and tertiary (highly specialized) medical care [Electronic resource] / Kravchenko V. V., Mishchenko T. S., Lishchyshina O. M. [et al.]; Ministry of Health of Ukraine. Kyiv, 2016. 86 p. Access to the resource: http://www.moz.gov.ua/ua/portal/dn_20160222_1.html.
  6. Schmid, T. E., Yakhno, N. N. Multiple Sclerosis: A Guide for Physicians. Moscow: MEDpress-inform, 2012. 272 p.
  7. Murray J. Multiple sclerosis — the history of a disease. N. Y. : Demos Medical Publishing, 2005. 168 p.
  8. Birnbaum G. Multiple sclerosis. Clinical guide to diagnosis and treatment. Oxford University Press, 2013. 152 p.
  9. Sokolova L. I. Multiple sclerosis: historical overview and scientific and practical development of the problem // Health of Ukraine. 2016. No. 1. Pp. 44–48.
  10. Alekseeva T. G., Boiko A. N., Gusev E. & I. Spectrum of neuropsychological changes in multiple sclerosis // Journal of Neurology and Psychiatry. 2000. No. 11. P. 15–20.
  11. Schmidt T. E. Cognitive impairments and attempts to correct them in multiple sclerosis // Ibid. 2005. No. 9. Pp. 54–56.
  12. Zavalishin I. A. Multiple sclerosis: selected issues of theory and practice. - М., 2000. - 640 с.
  13. Cognitive profile of patients with multiple sclerosis / Litvinenko N. V., Pinchuk V. A., Silenko G. Ya. [et al.] // Problems of Ecology and Medicine. 2012. Vol. 16. No. 3—4. P. 13—15)
  14. Negrich T. I. Cognitive disorders in multiple sclerosis // Health of Ukraine. 2010. P. 29.
  15. Lytvynenko N.V. Efficacy of neuromidine in the complex therapy of cognitive disorders in patients with relapsing-remitting multiple sclerosis / N.V. Lytvynenko, V.A. Pinchuk, G.Y. Silenko // Ukrainian Journal of Psychoneurology. 2013. Vol. 21, No. 4 (77). С. 130-132. URL:
  16. Kirilyuk S. Y. Cognitive impairments in patients with multiple sclerosis and their dependence on social and demographic factors // Ibid. 2015. Issue 23 (1). Pp. 56–65.
  17. Drew M., Tippett J., Starkey  N.  J., Isler R.  B.  Executive dysfunction and cognitive impairment in a large community-based sample with multiple sclerosis form New  Zealand: a  descriptive study // Arch. Clin Neuropsychol. 2008. Vol. 23. P. 1—19.
  18. Zupanets I. A., Shebeko S. K., Opryshko I. A. Pharmacodynamic aspects of the neuroprotective synergism of the drug "Olatropil" // Ukrainian Journal of Psychoneurology. 2016. Vol. 24, issue 2 (87). Pp. 113–116.
  19. Morozova O. G., Yaroshevsky A. A., Lipinskaya Ya. V. The effect of Olatropil on cognitive, vegetative, and psychoemotional indicators in individuals with chronic cerebral ischemia against a background of arterial hypertension // International Neurological Journal. 2015. No. 3. Pp. 61–67.
  20. Ostrovskaya, R. U. Nootropic properties of derivatives of gammaaminobutyric acid / R. U. Ostrovskaya, S. S. Trofimov // Bul. Experim. biol. med. - 1984. - № 12. - С. 170-172.
  21. Ellergast J. Gamma-aminobutyric acid — mediated neurophysiological effects in  the central nervous system  // Brain neurophysiology. Chicago : Illinois Univ. Press, 2000. P. 497—530.
  22. Kurtzke J. Rating neurologic impairment in Multiple sclerosis: an expanded disability status scale (EDSS) // Neurology. 1983; 33; 1444—1452.
  23. Polishchuk, I. A., Vidrenko, I. A. Atlas for experimental research into deviations in human mental activity. 2nd ed. Kyiv: Zdorovya, 1980. 156 p.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»